Repatriation Medical Authority – Notice of Investigation – Ischaemic Heart Disease – focussed

Overview

The Veterans' Entitlements Act 1986 (VEA) was enacted to provide for the payment of pensions and other benefits to veterans and their families, addressing the need for support and recognition of service-related disabilities and hardships. The Repatriation Medical Authority (the Authority) under this Act, has announced its intention to conduct an investigation regarding the relationship between psoriasis, psoriatic arthritis, and ischaemic heart disease. This initiative aims to further the understanding and potential recognition of these conditions as factors in ischaemic heart disease, aligning with the provisions of Statements of Principles Instrument Nos. 1 and 2 of 2016. The Authority, in its capacity to review and update medical principles affecting veterans' entitlements, invites submissions from eligible claimants, relevant organisations, and experts to aid in this investigation. The policy objective is to ensure that veterans' health conditions are comprehensively assessed and appropriately recognised in the context of their entitlements under the VEA.

Scope and Application

The Repatriation Medical Authority (the Authority) under section 196G of the Veterans' Entitlements Act 1986 (VEA) has announced its intention to investigate the correlation between psoriasis, psoriatic arthritis, and ischaemic heart disease. This investigation is relevant to Statements of Principles Instrument Nos. 1 and 2 of 2016, which pertain to ischaemic heart disease. The scope of this investigation includes inviting submissions from various stakeholders, including individuals eligible for claims under the VEA or the Military Rehabilitation and Compensation Act 2004, organisations representing veterans or their dependants, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and experts in relevant fields. The Authority is extending an opportunity for these entities and persons to contribute written submissions by 18 June 2021, with options for electronic submission via the RMA website, email, or postal mail. The Authority will commence its first meeting for this investigation on 7 July 2021. This legislative action is within the Commonwealth jurisdiction and does not specify any exclusions, exemptions, or thresholds, and its application may be further defined through subordinate instruments.

Key Provisions

The main operative sections of the Notice of Investigation (Gazette) under the Veterans' Entitlements Act 1986 (VEA) pertain to section 196G, which provides for the initiation of an investigation into the relationship between psoriasis, psoriatic arthritis, and ischaemic heart disease. The investigation is being undertaken in the context of the Statements of Principles Instrument Nos. 1 and 2 of 2016, as amended, concerning ischaemic heart disease (section 196G(1)). The Repatriation Medical Authority (the Authority) has invited various stakeholders, including veterans, representatives of veterans, and experts in relevant fields, to make written submissions by 18 June 2021, with options for electronic, email, or postal submissions provided (section 196G(2)-(4)). The Authority's first meeting for this investigation is scheduled for 7 July 2021 (section 196G(5)). The Notice imposes several obligations on the parties it governs. Firstly, eligible claimants under Part II or Part IV of the VEA, claimants under section 319 of the Military Rehabilitation and Compensation Act 2004 (MRCA), representatives of veterans and related groups, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and experts with relevant expertise are invited to submit written submissions (section 196G(2)-(4)). These submissions must be received by the Authority by the specified deadline, which is 18 June 2021 (section 196G(4)). Furthermore, the Notice provides clear instructions on how to submit these written submissions, including the use of the RMA website, email, or postal mail, and directs interested parties to the RMA Submission Guidelines for further guidance (section 196G(4)). Breach of the obligations set forth in the Notice of Investigation could lead to various civil or administrative consequences. While the Notice does not explicitly state penalties for failure to comply with submission requirements, non-compliance may affect the relevance and consideration of the submissions in the investigation process. The Authority may choose to disregard submissions that do not meet the specified criteria or are submitted after the deadline. However, the Notice does not outline specific penalties for such non-compliance, and the consequences would be determined by the Authority in the context of the investigation. The Notice does not explicitly mention criminal or civil penalties for breaches. However, it is implied that failure to adhere to the submission guidelines and deadlines may impact the relevance and consideration of the submissions in the investigation process. The Notice does not provide specific details about potential consequences for non-compliance beyond the general requirement for written submissions by the deadline. Therefore, while there are no stated maximum penalties, non-compliance may lead to the exclusion of submissions from the investigation, potentially affecting the outcomes of the investigation.